Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 2/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4700830 | 0.90 | MCHR1 (0.38) | GCKMCHR1TP53PPARAPPARD | |
| SCHEMBL4700751 | 0.87 | GCK (0.41) | GCKMAPTMCHR1KDM4EL3MBTL1 | |
| SCHEMBL3569793 | 0.86 | GCK (0.40) | GCKMAPTMCHR1KDM4EL3MBTL1 | |
| SCHEMBL4701518 | 0.82 | MAPT (0.44) | MAPTTP53POLB | |
| SCHEMBL4704618 | 0.79 | GCK (0.37) | GCKMAPTMCHR1TP53KDM4E | |
| SCHEMBL3572679 | 0.78 | DGAT1 (0.42) | GCKMCHR1KDM4EL3MBTL1 | |
| SCHEMBL3577884 | 0.77 | GCK (0.41) | GCKMAPTMCHR1KDM4EL3MBTL1 | |
| SCHEMBL3576199 | 0.77 | PPARG (0.40) | MCHR1PPARAPPARDPPARG | |
| SCHEMBL333883 | 0.77 | FAAH (0.38) | KDM4ETHRBPPARAPPARDPPARG | |
| SCHEMBL3573660 | 0.76 | FAAH (0.40) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778633-B1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| US-20080188473-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2008-08-07 | — | — | US | disclosed |
| WO-2008082725-A1 | PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188473-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, PTGS1, PTGER1 | GCK 2750/4885MAPT 3535/4885MCHR1 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.